img

Global PD-1&PD-L1 Immunotherapy Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global PD-1&PD-L1 Immunotherapy Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

A protein found on T cells (a type of immune cell) that helps keep the body's immune responses in check. When PD-1 is bound to another protein called PD-L1, it helps keep T cells from killing other cells, including cancer cells. Some anticancer drugs, called immune checkpoint inhibitors, are used to block PD-1.
PD-1&PD-L1 Immunotherapy report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global PD-1&PD-L1 Immunotherapy market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Non-Small Cell Lung Cancer and Esophageal Cancer are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for PD-1&PD-L1 Immunotherapy industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, PD-1&PD-L1 Immunotherapy key manufacturers include AstraZeneca Plc, BeiGene, Ltd., Bristol-Myers Squibb Company, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Eli Lilly & Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Innovent Biologics, Inc. and Jiangsu HengRui Medicine Co., Ltd., etc. AstraZeneca Plc, BeiGene, Ltd., Bristol-Myers Squibb Company are top 3 players and held % sales share in total in 2022.
PD-1&PD-L1 Immunotherapy can be divided into PD-1 Inhibitors and PD-L1 Inhibitors, etc. PD-1 Inhibitors is the mainstream product in the market, accounting for % sales share globally in 2022.
PD-1&PD-L1 Immunotherapy is widely used in various fields, such as Non-Small Cell Lung Cancer, Esophageal Cancer, Urothelial Carcinoma and Hepatocellular Carcinoma, etc. Non-Small Cell Lung Cancer provides greatest supports to the PD-1&PD-L1 Immunotherapy industry development. In 2022, global % sales of PD-1&PD-L1 Immunotherapy went into Non-Small Cell Lung Cancer filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global PD-1&PD-L1 Immunotherapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


AstraZeneca Plc
BeiGene, Ltd.
Bristol-Myers Squibb Company
Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
Eli Lilly & Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Innovent Biologics, Inc.
Jiangsu HengRui Medicine Co., Ltd.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Sanofi S.A.
Segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors

Segment by Application


Non-Small Cell Lung Cancer
Esophageal Cancer
Urothelial Carcinoma
Hepatocellular Carcinoma
Small Cell Lung Cancer
Others

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the PD-1&PD-L1 Immunotherapy market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of PD-1&PD-L1 Immunotherapy, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the PD-1&PD-L1 Immunotherapy industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of PD-1&PD-L1 Immunotherapy in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, PD-1&PD-L1 Immunotherapy introduction, etc. PD-1&PD-L1 Immunotherapy Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of PD-1&PD-L1 Immunotherapy market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.

Table of Content

1 PD-1&PD-L1 Immunotherapy Market Overview
1.1 PD-1&PD-L1 Immunotherapy Product Overview
1.2 PD-1&PD-L1 Immunotherapy Market Segment by Type
1.2.1 PD-1 Inhibitors
1.2.2 PD-L1 Inhibitors
1.3 Global PD-1&PD-L1 Immunotherapy Market Size by Type
1.3.1 Global PD-1&PD-L1 Immunotherapy Market Size Overview by Type (2018-2034)
1.3.2 Global PD-1&PD-L1 Immunotherapy Historic Market Size Review by Type (2018-2024)
1.3.3 Global PD-1&PD-L1 Immunotherapy Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America PD-1&PD-L1 Immunotherapy Sales Breakdown by Type (2018-2024)
1.4.2 Europe PD-1&PD-L1 Immunotherapy Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Breakdown by Type (2018-2024)
1.4.4 Latin America PD-1&PD-L1 Immunotherapy Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Breakdown by Type (2018-2024)
2 Global PD-1&PD-L1 Immunotherapy Market Competition by Company
2.1 Global Top Players by PD-1&PD-L1 Immunotherapy Sales (2018-2024)
2.2 Global Top Players by PD-1&PD-L1 Immunotherapy Revenue (2018-2024)
2.3 Global Top Players by PD-1&PD-L1 Immunotherapy Price (2018-2024)
2.4 Global Top Manufacturers PD-1&PD-L1 Immunotherapy Manufacturing Base Distribution, Sales Area, Product Type
2.5 PD-1&PD-L1 Immunotherapy Market Competitive Situation and Trends
2.5.1 PD-1&PD-L1 Immunotherapy Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by PD-1&PD-L1 Immunotherapy Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in PD-1&PD-L1 Immunotherapy as of 2022)
2.7 Date of Key Manufacturers Enter into PD-1&PD-L1 Immunotherapy Market
2.8 Key Manufacturers PD-1&PD-L1 Immunotherapy Product Offered
2.9 Mergers & Acquisitions, Expansion
3 PD-1&PD-L1 Immunotherapy Status and Outlook by Region
3.1 Global PD-1&PD-L1 Immunotherapy Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global PD-1&PD-L1 Immunotherapy Historic Market Size by Region
3.2.1 Global PD-1&PD-L1 Immunotherapy Sales in Volume by Region (2018-2024)
3.2.2 Global PD-1&PD-L1 Immunotherapy Sales in Value by Region (2018-2024)
3.2.3 Global PD-1&PD-L1 Immunotherapy Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global PD-1&PD-L1 Immunotherapy Forecasted Market Size by Region
3.3.1 Global PD-1&PD-L1 Immunotherapy Sales in Volume by Region (2024-2034)
3.3.2 Global PD-1&PD-L1 Immunotherapy Sales in Value by Region (2024-2034)
3.3.3 Global PD-1&PD-L1 Immunotherapy Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global PD-1&PD-L1 Immunotherapy by Application
4.1 PD-1&PD-L1 Immunotherapy Market Segment by Application
4.1.1 Non-Small Cell Lung Cancer
4.1.2 Esophageal Cancer
4.1.3 Urothelial Carcinoma
4.1.4 Hepatocellular Carcinoma
4.1.5 Small Cell Lung Cancer
4.1.6 Others
4.2 Global PD-1&PD-L1 Immunotherapy Market Size by Application
4.2.1 Global PD-1&PD-L1 Immunotherapy Market Size Overview by Application (2018-2034)
4.2.2 Global PD-1&PD-L1 Immunotherapy Historic Market Size Review by Application (2018-2024)
4.2.3 Global PD-1&PD-L1 Immunotherapy Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America PD-1&PD-L1 Immunotherapy Sales Breakdown by Application (2018-2024)
4.3.2 Europe PD-1&PD-L1 Immunotherapy Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Breakdown by Application (2018-2024)
4.3.4 Latin America PD-1&PD-L1 Immunotherapy Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Breakdown by Application (2018-2024)
5 North America PD-1&PD-L1 Immunotherapy by Country
5.1 North America PD-1&PD-L1 Immunotherapy Historic Market Size by Country
5.1.1 North America PD-1&PD-L1 Immunotherapy Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America PD-1&PD-L1 Immunotherapy Sales in Volume by Country (2018-2024)
5.1.3 North America PD-1&PD-L1 Immunotherapy Sales in Value by Country (2018-2024)
5.2 North America PD-1&PD-L1 Immunotherapy Forecasted Market Size by Country
5.2.1 North America PD-1&PD-L1 Immunotherapy Sales in Volume by Country (2024-2034)
5.2.2 North America PD-1&PD-L1 Immunotherapy Sales in Value by Country (2024-2034)
6 Europe PD-1&PD-L1 Immunotherapy by Country
6.1 Europe PD-1&PD-L1 Immunotherapy Historic Market Size by Country
6.1.1 Europe PD-1&PD-L1 Immunotherapy Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe PD-1&PD-L1 Immunotherapy Sales in Volume by Country (2018-2024)
6.1.3 Europe PD-1&PD-L1 Immunotherapy Sales in Value by Country (2018-2024)
6.2 Europe PD-1&PD-L1 Immunotherapy Forecasted Market Size by Country
6.2.1 Europe PD-1&PD-L1 Immunotherapy Sales in Volume by Country (2024-2034)
6.2.2 Europe PD-1&PD-L1 Immunotherapy Sales in Value by Country (2024-2034)
7 Asia-Pacific PD-1&PD-L1 Immunotherapy by Region
7.1 Asia-Pacific PD-1&PD-L1 Immunotherapy Historic Market Size by Region
7.1.1 Asia-Pacific PD-1&PD-L1 Immunotherapy Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific PD-1&PD-L1 Immunotherapy Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific PD-1&PD-L1 Immunotherapy Sales in Value by Region (2018-2024)
7.2 Asia-Pacific PD-1&PD-L1 Immunotherapy Forecasted Market Size by Region
7.2.1 Asia-Pacific PD-1&PD-L1 Immunotherapy Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific PD-1&PD-L1 Immunotherapy Sales in Value by Region (2024-2034)
8 Latin America PD-1&PD-L1 Immunotherapy by Country
8.1 Latin America PD-1&PD-L1 Immunotherapy Historic Market Size by Country
8.1.1 Latin America PD-1&PD-L1 Immunotherapy Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America PD-1&PD-L1 Immunotherapy Sales in Volume by Country (2018-2024)
8.1.3 Latin America PD-1&PD-L1 Immunotherapy Sales in Value by Country (2018-2024)
8.2 Latin America PD-1&PD-L1 Immunotherapy Forecasted Market Size by Country
8.2.1 Latin America PD-1&PD-L1 Immunotherapy Sales in Volume by Country (2024-2034)
8.2.2 Latin America PD-1&PD-L1 Immunotherapy Sales in Value by Country (2024-2034)
9 Middle East and Africa PD-1&PD-L1 Immunotherapy by Country
9.1 Middle East and Africa PD-1&PD-L1 Immunotherapy Historic Market Size by Country
9.1.1 Middle East and Africa PD-1&PD-L1 Immunotherapy Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa PD-1&PD-L1 Immunotherapy Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa PD-1&PD-L1 Immunotherapy Sales in Value by Country (2018-2024)
9.2 Middle East and Africa PD-1&PD-L1 Immunotherapy Forecasted Market Size by Country
9.2.1 Middle East and Africa PD-1&PD-L1 Immunotherapy Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa PD-1&PD-L1 Immunotherapy Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 AstraZeneca Plc
10.1.1 AstraZeneca Plc Company Information
10.1.2 AstraZeneca Plc Introduction and Business Overview
10.1.3 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2024)
10.1.4 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Products Offered
10.1.5 AstraZeneca Plc Recent Development
10.2 BeiGene, Ltd.
10.2.1 BeiGene, Ltd. Company Information
10.2.2 BeiGene, Ltd. Introduction and Business Overview
10.2.3 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2024)
10.2.4 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Products Offered
10.2.5 BeiGene, Ltd. Recent Development
10.3 Bristol-Myers Squibb Company
10.3.1 Bristol-Myers Squibb Company Company Information
10.3.2 Bristol-Myers Squibb Company Introduction and Business Overview
10.3.3 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Products Offered
10.3.5 Bristol-Myers Squibb Company Recent Development
10.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
10.4.1 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Information
10.4.2 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Introduction and Business Overview
10.4.3 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Products Offered
10.4.5 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Recent Development
10.5 Eli Lilly & Company
10.5.1 Eli Lilly & Company Company Information
10.5.2 Eli Lilly & Company Introduction and Business Overview
10.5.3 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Products Offered
10.5.5 Eli Lilly & Company Recent Development
10.6 F. Hoffmann-La Roche Ltd
10.6.1 F. Hoffmann-La Roche Ltd Company Information
10.6.2 F. Hoffmann-La Roche Ltd Introduction and Business Overview
10.6.3 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2024)
10.6.4 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Products Offered
10.6.5 F. Hoffmann-La Roche Ltd Recent Development
10.7 GlaxoSmithKline plc
10.7.1 GlaxoSmithKline plc Company Information
10.7.2 GlaxoSmithKline plc Introduction and Business Overview
10.7.3 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2024)
10.7.4 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Products Offered
10.7.5 GlaxoSmithKline plc Recent Development
10.8 Innovent Biologics, Inc.
10.8.1 Innovent Biologics, Inc. Company Information
10.8.2 Innovent Biologics, Inc. Introduction and Business Overview
10.8.3 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Products Offered
10.8.5 Innovent Biologics, Inc. Recent Development
10.9 Jiangsu HengRui Medicine Co., Ltd.
10.9.1 Jiangsu HengRui Medicine Co., Ltd. Company Information
10.9.2 Jiangsu HengRui Medicine Co., Ltd. Introduction and Business Overview
10.9.3 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Products Offered
10.9.5 Jiangsu HengRui Medicine Co., Ltd. Recent Development
10.10 Merck & Co., Inc.
10.10.1 Merck & Co., Inc. Company Information
10.10.2 Merck & Co., Inc. Introduction and Business Overview
10.10.3 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Products Offered
10.10.5 Merck & Co., Inc. Recent Development
10.11 Novartis AG
10.11.1 Novartis AG Company Information
10.11.2 Novartis AG Introduction and Business Overview
10.11.3 Novartis AG PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2024)
10.11.4 Novartis AG PD-1&PD-L1 Immunotherapy Products Offered
10.11.5 Novartis AG Recent Development
10.12 Pfizer Inc.
10.12.1 Pfizer Inc. Company Information
10.12.2 Pfizer Inc. Introduction and Business Overview
10.12.3 Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2024)
10.12.4 Pfizer Inc. PD-1&PD-L1 Immunotherapy Products Offered
10.12.5 Pfizer Inc. Recent Development
10.13 Regeneron Pharmaceuticals Inc.
10.13.1 Regeneron Pharmaceuticals Inc. Company Information
10.13.2 Regeneron Pharmaceuticals Inc. Introduction and Business Overview
10.13.3 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2024)
10.13.4 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Products Offered
10.13.5 Regeneron Pharmaceuticals Inc. Recent Development
10.14 Sanofi S.A.
10.14.1 Sanofi S.A. Company Information
10.14.2 Sanofi S.A. Introduction and Business Overview
10.14.3 Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales, Revenue and Gross Margin (2018-2024)
10.14.4 Sanofi S.A. PD-1&PD-L1 Immunotherapy Products Offered
10.14.5 Sanofi S.A. Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 PD-1&PD-L1 Immunotherapy Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 PD-1&PD-L1 Immunotherapy Industrial Chain Analysis
11.4 PD-1&PD-L1 Immunotherapy Market Dynamics
11.4.1 PD-1&PD-L1 Immunotherapy Industry Trends
11.4.2 PD-1&PD-L1 Immunotherapy Market Drivers
11.4.3 PD-1&PD-L1 Immunotherapy Market Challenges
11.4.4 PD-1&PD-L1 Immunotherapy Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 PD-1&PD-L1 Immunotherapy Distributors
12.3 PD-1&PD-L1 Immunotherapy Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of PD-1 Inhibitors
Table 2. Major Company of PD-L1 Inhibitors
Table 3. Global PD-1&PD-L1 Immunotherapy Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 4. Global PD-1&PD-L1 Immunotherapy Sales by Type (2018-2024) & (Units)
Table 5. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Type (2018-2024)
Table 6. Global PD-1&PD-L1 Immunotherapy Sales by Type (2018-2024) & (US& Million)
Table 7. Global PD-1&PD-L1 Immunotherapy Market Share in Value by Type (2018-2024)
Table 8. Global PD-1&PD-L1 Immunotherapy Price by Type (2018-2024) & (US$/Unit)
Table 9. Global PD-1&PD-L1 Immunotherapy Sales by Type (2024-2034) & (Units)
Table 10. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Type (2024-2034)
Table 11. Global PD-1&PD-L1 Immunotherapy Sales by Type (2024-2034) & (US$ Million)
Table 12. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Type (2024-2034)
Table 13. Global PD-1&PD-L1 Immunotherapy Price by Type (2024-2034) & (US$/Unit)
Table 14. North America PD-1&PD-L1 Immunotherapy Sales by Type (2018-2024) & (Units)
Table 15. North America PD-1&PD-L1 Immunotherapy Sales by Type (2018-2024) & (US$ Million)
Table 16. Europe PD-1&PD-L1 Immunotherapy Sales (Units) by Type (2018-2024)
Table 17. Europe PD-1&PD-L1 Immunotherapy Sales by Type (2018-2024) & (US$ Million)
Table 18. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales (Units) by Type (2018-2024)
Table 19. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales by Type (2018-2024) & (US$ Million)
Table 20. Latin America PD-1&PD-L1 Immunotherapy Sales (Units) by Type (2018-2024)
Table 21. Latin America PD-1&PD-L1 Immunotherapy Sales by Type (2018-2024) & (US$ Million)
Table 22. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales (Units) by Type (2018-2024)
Table 23. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Type (2018-2024) & (US$ Million)
Table 24. Global PD-1&PD-L1 Immunotherapy Sales by Company (2018-2024) & (Units)
Table 25. Global PD-1&PD-L1 Immunotherapy Sales Share by Company (2018-2024)
Table 26. Global PD-1&PD-L1 Immunotherapy Revenue by Company (2018-2024) & (US$ Million)
Table 27. Global PD-1&PD-L1 Immunotherapy Revenue Share by Company (2018-2024)
Table 28. Global Market PD-1&PD-L1 Immunotherapy Price by Company (2018-2024) & (US$/Unit)
Table 29. Global PD-1&PD-L1 Immunotherapy Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 30. Global PD-1&PD-L1 Immunotherapy Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 31. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in PD-1&PD-L1 Immunotherapy as of 2022)
Table 32. Date of Key Manufacturers Enter into PD-1&PD-L1 Immunotherapy Market
Table 33. Key Manufacturers PD-1&PD-L1 Immunotherapy Product Type
Table 34. Mergers & Acquisitions, Expansion Plans
Table 35. Global PD-1&PD-L1 Immunotherapy Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 36. Global PD-1&PD-L1 Immunotherapy Sales by Region (2018-2024) & (Units)
Table 37. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Region (2018-2024)
Table 38. Global PD-1&PD-L1 Immunotherapy Sales by Region (2018-2024) & (US$ Million)
Table 39. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Region (2018-2024)
Table 40. Global PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 41. Global PD-1&PD-L1 Immunotherapy Sales by Region (2024-2034) & (Units)
Table 42. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Region (2024-2034)
Table 43. Global PD-1&PD-L1 Immunotherapy Sales by Region (2024-2034) & (US$ Million)
Table 44. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Region (2024-2034)
Table 45. Global PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2034)
Table 46. Global PD-1&PD-L1 Immunotherapy Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 47. Global PD-1&PD-L1 Immunotherapy Sales by Application (2018-2024) & (Units)
Table 48. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Application (2018-2024)
Table 49. Global PD-1&PD-L1 Immunotherapy Sales by Application (2018-2024) & (US$ Million)
Table 50. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Application (2018-2024)
Table 51. Global PD-1&PD-L1 Immunotherapy Price by Application (2018-2024) & (US$/Unit)
Table 52. Global PD-1&PD-L1 Immunotherapy Sales by Application (2024-2034) & (Units)
Table 53. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Application (2024-2034)
Table 54. Global PD-1&PD-L1 Immunotherapy Sales by Application (2024-2034) & (US$ Million)
Table 55. Global PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Application (2024-2034)
Table 56. Global PD-1&PD-L1 Immunotherapy Price by Application (2024-2034) & (US$/Unit)
Table 57. North America PD-1&PD-L1 Immunotherapy Sales by Application (2018-2024) (Units)
Table 58. North America PD-1&PD-L1 Immunotherapy Sales by Application (2018-2024) & (US$ Million)
Table 59. Europe PD-1&PD-L1 Immunotherapy Sales by Application (2018-2024) (Units)
Table 60. Europe PD-1&PD-L1 Immunotherapy Sales by Application (2018-2024) & (US$ Million)
Table 61. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales by Application (2018-2024) (Units)
Table 62. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales by Application (2018-2024) & (US$ Million)
Table 63. Latin America PD-1&PD-L1 Immunotherapy Sales by Application (2018-2024) (Units)
Table 64. Latin America PD-1&PD-L1 Immunotherapy Sales by Application (2018-2024) & (US$ Million)
Table 65. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Application (2018-2024) (Units)
Table 66. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Application (2018-2024) & (US$ Million)
Table 67. North America PD-1&PD-L1 Immunotherapy Sales by Country (2018-2024) & (Units)
Table 68. North America PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Country (2018-2024)
Table 69. North America PD-1&PD-L1 Immunotherapy Sales by Country (2018-2024) & (US$ Million)
Table 70. North America PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Country (2018-2024)
Table 71. North America PD-1&PD-L1 Immunotherapy Sales by Country (2024-2034) & (Units)
Table 72. North America PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Country (2024-2034)
Table 73. North America PD-1&PD-L1 Immunotherapy Sales by Country (2024-2034) & (US$ Million)
Table 74. North America PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Country (2024-2034)
Table 75. Europe PD-1&PD-L1 Immunotherapy Sales by Country (2018-2024) & (Units)
Table 76. Europe PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Country (2018-2024)
Table 77. Europe PD-1&PD-L1 Immunotherapy Sales by Country (2018-2024) & (US$ Million)
Table 78. Europe PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Country (2018-2024)
Table 79. Europe PD-1&PD-L1 Immunotherapy Sales by Country (2024-2034) & (Units)
Table 80. Europe PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Country (2024-2034)
Table 81. Europe PD-1&PD-L1 Immunotherapy Sales by Country (2024-2034) & (US$ Million)
Table 82. Europe PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Country (2024-2034)
Table 83. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales by Region (2018-2024) & (Units)
Table 84. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Region (2018-2024)
Table 85. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales by Region (2018-2024) & (US$ Million)
Table 86. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Region (2018-2024)
Table 87. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales by Region (2024-2034) & (Units)
Table 88. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Region (2024-2034)
Table 89. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales by Region (2024-2034) & (US$ Million)
Table 90. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Region (2024-2034)
Table 91. Latin America PD-1&PD-L1 Immunotherapy Sales by Country (2018-2024) & (Units)
Table 92. Latin America PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Country (2018-2024)
Table 93. Latin America PD-1&PD-L1 Immunotherapy Sales by Country (2018-2024) & (US$ Million)
Table 94. Latin America PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Country (2018-2024)
Table 95. Latin America PD-1&PD-L1 Immunotherapy Sales by Country (2024-2034) & (Units)
Table 96. Latin America PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Country (2024-2034)
Table 97. Latin America PD-1&PD-L1 Immunotherapy Sales by Country (2024-2034) & (US$ Million)
Table 98. Latin America PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Country (2024-2034)
Table 99. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Country (2018-2024) & (Units)
Table 100. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Country (2018-2024)
Table 101. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Country (2018-2024) & (US$ Million)
Table 102. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Country (2018-2024)
Table 103. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Country (2024-2034) & (Units)
Table 104. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Country (2024-2034)
Table 105. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales by Country (2024-2034) & (US$ Million)
Table 106. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Country (2024-2034)
Table 107. AstraZeneca Plc Company Information
Table 108. AstraZeneca Plc Introduction and Business Overview
Table 109. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product
Table 111. AstraZeneca Plc Recent Development
Table 112. BeiGene, Ltd. Company Information
Table 113. BeiGene, Ltd. Introduction and Business Overview
Table 114. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product
Table 116. BeiGene, Ltd. Recent Development
Table 117. Bristol-Myers Squibb Company Company Information
Table 118. Bristol-Myers Squibb Company Introduction and Business Overview
Table 119. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 120. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product
Table 121. Bristol-Myers Squibb Company Recent Development
Table 122. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Information
Table 123. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Introduction and Business Overview
Table 124. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 125. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product
Table 126. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Recent Development
Table 127. Eli Lilly & Company Company Information
Table 128. Eli Lilly & Company Introduction and Business Overview
Table 129. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 130. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product
Table 131. Eli Lilly & Company Recent Development
Table 132. F. Hoffmann-La Roche Ltd Company Information
Table 133. F. Hoffmann-La Roche Ltd Introduction and Business Overview
Table 134. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 135. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product
Table 136. F. Hoffmann-La Roche Ltd Recent Development
Table 137. GlaxoSmithKline plc Company Information
Table 138. GlaxoSmithKline plc Introduction and Business Overview
Table 139. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 140. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product
Table 141. GlaxoSmithKline plc Recent Development
Table 142. Innovent Biologics, Inc. Company Information
Table 143. Innovent Biologics, Inc. Introduction and Business Overview
Table 144. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 145. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product
Table 146. Innovent Biologics, Inc. Recent Development
Table 147. Jiangsu HengRui Medicine Co., Ltd. Company Information
Table 148. Jiangsu HengRui Medicine Co., Ltd. Introduction and Business Overview
Table 149. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 150. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product
Table 151. Jiangsu HengRui Medicine Co., Ltd. Recent Development
Table 152. Merck & Co., Inc. Company Information
Table 153. Merck & Co., Inc. Introduction and Business Overview
Table 154. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 155. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product
Table 156. Merck & Co., Inc. Recent Development
Table 157. Novartis AG Company Information
Table 158. Novartis AG Introduction and Business Overview
Table 159. Novartis AG PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 160. Novartis AG PD-1&PD-L1 Immunotherapy Product
Table 161. Novartis AG Recent Development
Table 162. Pfizer Inc. Company Information
Table 163. Pfizer Inc. Introduction and Business Overview
Table 164. Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 165. Pfizer Inc. PD-1&PD-L1 Immunotherapy Product
Table 166. Pfizer Inc. Recent Development
Table 167. Regeneron Pharmaceuticals Inc. Company Information
Table 168. Regeneron Pharmaceuticals Inc. Introduction and Business Overview
Table 169. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 170. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product
Table 171. Regeneron Pharmaceuticals Inc. Recent Development
Table 172. Sanofi S.A. Company Information
Table 173. Sanofi S.A. Introduction and Business Overview
Table 174. Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 175. Sanofi S.A. PD-1&PD-L1 Immunotherapy Product
Table 176. Sanofi S.A. Recent Development
Table 177. Key Raw Materials Lists
Table 178. Raw Materials Key Suppliers Lists
Table 179. PD-1&PD-L1 Immunotherapy Market Trends
Table 180. PD-1&PD-L1 Immunotherapy Market Drivers
Table 181. PD-1&PD-L1 Immunotherapy Market Challenges
Table 182. PD-1&PD-L1 Immunotherapy Market Restraints
Table 183. PD-1&PD-L1 Immunotherapy Distributors List
Table 184. PD-1&PD-L1 Immunotherapy Downstream Customers
Table 185. Research Programs/Design for This Report
Table 186. Key Data Information from Secondary Sources
Table 187. Key Data Information from Primary Sources
List of Figures
Figure 1. PD-1&PD-L1 Immunotherapy Product Picture
Figure 2. Global PD-1&PD-L1 Immunotherapy Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global PD-1&PD-L1 Immunotherapy Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global PD-1&PD-L1 Immunotherapy Sales Status and Outlook (2018-2034) & (Units)
Figure 5. Product Picture of PD-1 Inhibitors
Figure 6. Global PD-1 Inhibitors Sales YoY Growth (2018-2034) & (Units)
Figure 7. Product Picture of PD-L1 Inhibitors
Figure 8. Global PD-L1 Inhibitors Sales YoY Growth (2018-2034) & (Units)
Figure 9. Global PD-1&PD-L1 Immunotherapy Sales by Type (2018-2034) & (US$ Million)
Figure 10. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type in 2022 & 2034
Figure 11. North America PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Type in 2022
Figure 12. North America PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Type in 2022
Figure 13. Europe PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Type in 2022
Figure 14. Europe PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Type in 2022
Figure 15. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Type in 2022
Figure 16. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Type in 2022
Figure 17. Latin America PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Type in 2022
Figure 18. Latin America PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Type in 2022
Figure 19. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Type in 2022
Figure 20. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Type in 2022
Figure 21. The 5 and 10 Largest Manufacturers in the World: Market Share by PD-1&PD-L1 Immunotherapy Sales in 2022
Figure 22. The 5 and 10 Largest Manufacturers in the World: Market Share by PD-1&PD-L1 Immunotherapy Revenue in 2022
Figure 23. PD-1&PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 24. Product Picture of Non-Small Cell Lung Cancer
Figure 25. Global Non-Small Cell Lung Cancer Sales YoY Growth (2018-2034) & (Units)
Figure 26. Product Picture of Esophageal Cancer
Figure 27. Global Esophageal Cancer Sales YoY Growth (2018-2034) & (Units)
Figure 28. Product Picture of Urothelial Carcinoma
Figure 29. Global Urothelial Carcinoma Sales YoY Growth (2018-2034) & (Units)
Figure 30. Product Picture of Hepatocellular Carcinoma
Figure 31. Global Hepatocellular Carcinoma Sales YoY Growth (2018-2034) & (Units)
Figure 32. Product Picture of Small Cell Lung Cancer
Figure 33. Global Small Cell Lung Cancer Sales YoY Growth (2018-2034) & (Units)
Figure 34. Product Picture of Others
Figure 35. Global Others Sales YoY Growth (2018-2034) & (Units)
Figure 36. Global PD-1&PD-L1 Immunotherapy Sales by Application (2018-2034) & (US$ Million)
Figure 37. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application in 2022 & 2034
Figure 38. North America PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Application in 2022
Figure 39. North America PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Application in 2022
Figure 40. Europe PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Application in 2022
Figure 41. Europe PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Application in 2022
Figure 42. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Application in 2022
Figure 43. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Application in 2022
Figure 44. Latin America PD-1&PD-L1 Immunotherapy Sales Market Share in Volume by Application in 2022
Figure 45. Latin America PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Application in 2022
Figure 46. Middle East and Africa PD-1&PD-L1 Immunotherapy Sales Market Share in Value by Application in 2022
Figure 47. Key Raw Materials Price
Figure 48. PD-1&PD-L1 Immunotherapy Manufacturing Cost Structure
Figure 49. PD-1&PD-L1 Immunotherapy Industrial Chain Analysis
Figure 50. Channels of Distribution
Figure 51. Distributors Profiles
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries